Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FMmeds vs Medsol RX

FMmeds
Graded #257

Higher grade

vs+2.200000000000003
Medsol RX
Graded #306

Lower grade

The verdict

FMmeds takes it — 63.2/100 to 61/100.

FMmeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FMmeds is a Manhattan Beach-based DTC telehealth platform selling compounded semaglutide and tirzepatide co-formulated with vitamin B12, with no membership fee and a free initial visit billed only on approval.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFMmeds +1
46
45
Dose & formulationFMmeds +8
72
64
Clinical oversightMedsol RX +9
70
79
Labs & monitoringEven
53
53
FulfillmentFMmeds +14
97
83
Contract termsFMmeds +6
47
41
FMmeds · left barMedsol RX · right bar

The numbers

MetricFMmedsMedsol RX
WeighScore63.2/10061/100
GradeCC
Scorecard rank#257#306
Semaglutide$225/mo (all doses, compounded)$209/mo (compounded)
Tirzepatide$265/mo (all doses, compounded)$250/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FMmeds

Graded #257 · C

Strengths

  • All 50 states plus DC covered, stated in the Terms
  • Operating LLC and full Manhattan Beach, CA address disclosed
  • Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
  • Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
  • Flat pricing across all dose strengths — no dose-escalation surcharge

Where it loses points

  • Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
  • Clinical network not separately named
  • LegitScript Certified, but the specific ID isn't shown
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Medsol RX

Graded #306 · C

Strengths

  • Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
  • Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
  • Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
  • Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons

Where it loses points

  • Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
  • No legal entity name published on the site
  • Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
  • Compounded GLP-1s are not FDA-approved (the site discloses this)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard